## **I-Platelet Pooling Set**

The I-Platelet Pooling Set is manufactured by Kansuk and distributed by Cerus. It is available in two configurations:

- The octopus configuration with 9 tubing leads.
- The train configuration with 1 tubing lead.

The I-Platelet Pooling Set included in the double dose buffy coat platelet production process offers increased convenience and peace of mind.

#### No unnecessary ancillaries.

- Minimises risk of damage during handling.
- Minimises risk of dead volume during production.

# Optimised tubing lengths offer an ergonomic advantage.

### **Capillary tube**

The capillary tube that leads from the leukoreduction filter to the intermediate storage bag: • Enables flow control.

> Maximises leukoreduction performance.

#### Leukoreduction filter

Integrated Sepacell<sup>™</sup> PLX-5 leukoreduction filter from Asahi KASEI Medical Co., Ltd.

- With a proven track record in leukoreduction performance.<sup>2</sup>
- Validated for leukoreduction of up to 8 buffy coat platelet units.

#### Connect up to 8 buffy coats

- The octopus configuration has been validated to connect up to 8 buffy coats.
- Requires less space and allows for more convenient sterile docking.
- Saves time, as less washing with platelet additive solution (PAS) is required.

### Pooling bag

Comes with a 700 ml pooling bag

• Offers flexibility in the maximum buffy coat pool volume before centrifugation.

# Optimised design of the intermediate storage bag

 Reduces platelet loss during transfers as it has no unneccesary transfusion port.

#### **Global Headquarters**

Cerus Corporation 2550 Stanwell Drive Concord, CA 94520, USA +1 925 288 6000

#### **European Headquarters**

Cerus Europe B.V. Stationsstraat 79-D 3811 MH Amersfoort The Netherlands +31 33 496 0600

customer\_services@cerus.com www.interceptbloodsystem.com www.cerus.com

Adequate Leukodepletion of Platelet Concentrates from Pools of 7 or 8 Buffy-Coats for Photochemical Pathogen Inactivation Treatment of Double Transfusion Doses, ISBT2015, Maria Bergsten, Rut Norda

© 2017 Cerus Corporation. Cerus, INTERCEPT Blood System and INTERCEPT are trademarks of Cerus Corporation. Sepacell is a trademark of Asahi Kasei Medical Co., Ltd. MKT-EN 00281-02 v2.0 Use of INTERCEPT<sup>™</sup> plasma or platelets is contraindicated in patients with a history of allergic response to amotosalen or psoralens. Consult instructions for use for indications, contraindications, warnings and precautions.

